Literature DB >> 11517357

Phosphate supplementation for hypophosphataemia and parenteral nutrition.

W Hicks1, G Hardy.   

Abstract

Routine detection and treatment of acute hypophosphataemia is important in intensive care unit and many other hospitalized patients, but metabolic bone disease and hypophosphataemia are still experienced as a result of parenteral nutrition. A significantly common problem that faces the compounding pharmacist when formulating parenteral nutrition regimens is the difficulty associated with the successful avoidance of calcium phosphate precipitation. Although incorporation of the normal calcium and phosphate requirements into regimens for metabolically stable adults is usually achievable, it can prove impossible in paediatric and neonatal mixtures when using the standard inorganic sources that are currently licensed for use in the UK and USA. In other countries, where organic compounds are routinely available, this problem does not exist.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517357     DOI: 10.1097/00075197-200105000-00010

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  3 in total

1.  Factors contributing to the development of hypophosphataemia when refeeding using parenteral nutrition.

Authors:  Vanessa A Marvin; David Brown; Jane Portlock; Callum Livingstone
Journal:  Pharm World Sci       Date:  2008-03-30

2.  Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy.

Authors:  Stéphan Troyanov; David Geadah; Marc Ghannoum; Jean Cardinal; Martine Leblanc
Journal:  Intensive Care Med       Date:  2004-05-20       Impact factor: 17.440

3.  Influence of the calcium concentration in the presence of organic phosphorus on the physicochemical compatibility and stability of all-in-one admixtures for neonatal use.

Authors:  Daniela de Oliveira Ribeiro; Bianca Waruar Lobo; Nádia Maria Volpato; Venício Féo da Veiga; Lúcio Mendes Cabral; Valeria Pereira de Sousa
Journal:  Nutr J       Date:  2009-10-26       Impact factor: 3.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.